New mid-term targets lift Lonza shares

By Reuters News

** Swiss contract drug manufacturer Lonza LONN.S rises 2.2% after setting new mid-term targets and confirming its 2026 outlook

** Lonza targets 10% to 13% organic sales growth and a core EBITDA margin in the high thirties in the medium term

** Vontobel says the updated targets imply some upside to its estimates and sees free cash flow conversion improving

** Zuercher Kantonalbank highlights that the new margin ambitions are significantly higher than the market had expected

** Lonza shares are up around 8% this year, with 24 of 26 analysts rating it “buy” or “strong buy"

($1 = 0.8319 Swiss francs)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.